Skip to main content
Premium Trial:

Request an Annual Quote

Intrinsic Bioprobes and Biacore to Trade Know-How on SPR/MS


Intrinsic Bioprobes formally joined Biacore and Bruker Daltonics in their effort to develop and commercialize a combined surface plasmon resonance (SPR) and MALDI-TOF mass spectrometry system, the company said last week.

Although Intrinsic CEO Randall Nelson first began working with Biacore on SPR/MS in the late 90s, most of the development over the past few years has come from groups working independently with support from National Cancer Institute phase I and II SBIR grants, said Dobrin Nedelkov, a senior scientist for Intrinsic involved with the research.

The new agreement seeks to bring the companies more closely together in an effort to produce new intellectual property for a new SPR/MS system, Nedelkov said. While Intrinsic may not ultimately participate in manufacturing a commercially-available instrument, both Intrinsic and Biacore also collaborate with Bruker, creating a triumvirate of expertise for developing any product.

Intrinsic's contribution to the development team, Nedelkov said, is in the fundamental technology required for combining the two analysis systems on a single platform. Nelson has co-authored over twenty papers describing methods for integrating SPR and MS, Nedelkov said, making the company the “principal movers and shakers” in the field.

In particular, Intrinsic has created techniques for applying the MALDI matrix to SPR samples without destroying the spatial resolution of the samples arrayed on the chip, Nedelkov said. In addition, the company has modified the SPR chip geometry to allow easy transfer between the SPR and mass spectrometry steps of the analysis.


The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.